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Abstract
Background: CD137 and its ligand (CD137L) are potent immunoregulatory molecules that influence activation, proliferation,
differentiation and cell death of leukocytes. Expression of CD137 is upregulated in the lamina propria cells of Crohn’s
disease patients. Here, the role of CD137 in acute Dextran-Sodium-Sulfate (DSS)-induced colitis in mice was examined.
Methods: We induced acute large bowel inflammation (colitis) via DSS administration in CD1372/2 and wild-type (WT) mice.
Colitis severity was evaluated by clinical parameters (weight loss), cytokine secretion in colon segment cultures, and scoring
of histological inflammatory parameters. Additionally, populations of lamina propria mononuclear cells (LPMNC) and
intraepithelial lymphocytes (IEL) were characterized by flow cytometry. In a subset of mice, resolution of intestinal
inflammation was evaluated 3 and 7 days after withdrawal of DSS.
Results: We found that both CD1372/2 and WT mice demonstrated a similar degree of inflammation after 5 days of DSS
exposure. However, the resolution of colonic inflammation was impaired in the absence of CD137. This was accompanied by
a higher histological score of inflammation, and increased release of the pro-inflammatory mediators granulocyte
macrophage colony-stimulating factor (GM-CSF), CXCL1, IL-17 and IFN-c. Further, there were significantly more neutrophils
among the LPMNC of CD1372/2 mice, and reduced numbers of macrophages among the IEL.
Conclusion: We conclude that CD137 plays an essential role in the resolution of acute DSS-induced intestinal inflammation
in mice.
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Introduction
CD137 (TNFRS9, 4-1BB) is a member of the tumor necrosis
factor (TNF) receptor family, and CD137 ligand (CD137L) is a
member of the TNF superfamily. CD137 and its ligand are
expressed mostly on immune cells, and the CD137 receptor/
ligand system regulates activation, proliferation, differentiation
and cell death of leukocytes [1,2,3,4]. CD137 is expressed
activation-dependently on T cells, where it acts as a potent
costimulatory molecule [5]. Crosslinking of CD137 enhances T
cell activity sufficiently to induce rejection of tumors or transplants
[6,7]. Surprisingly, the very same agonistic anti-CD137 antibodies
have been demonstrated to ameliorate disease severity in various
murine models of autoimmune diseases [8,9,10].
Human inflammatory bowel diseases (IBD) are autoimmune
diseases that are characterized by chronic autoinflammatory
processes within the intestinal mucosal lamina propria. TNF has
been demonstrated to play a key role in human IBD [11,12,13]
and in experimental models of autoimmune colitis in mice [14,15],
where TNF induces intestinal epithelial cell apoptosis during
intestinal inflammation, thereby aggravating the disease [16]. Of
note, CD137L signaling has been demonstrated to induce TNF
secretion [17,18], and TNF receptor 1 (TNFR1) acts as a
coreceptor for CD137L and mediates CD137L signaling [19].
CD137 is induced in human IBD and in murine models of
intestinal inflammation [20,21]. However, the impact of CD137
and CD137L on experimental colitis in mice as well as in human
IBD is not known.
In the current study, we induced acute large bowel inflamma-
tion (colitis) via Dextran Sodium Sulfate (DSS) exposure in
CD1372/2 and WT mice. We found that while both CD1372/2
and WT mice demonstrated a similar degree of inflammation after
5 days of DSS exposure, the resolution of colonic inflammation
was significantly impaired in CD1372/2 mice. This was accom-
panied by increased histological signs of inflammation, increased
levels of the pro-inflammatory mediators GM-CSF, CXCL1, IL-
17 and IFN-c as well as increased neutrophil recruitment and
reduced macrophage numbers in the colonic lamina propria of
CD1372/2 mice.
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Materials and Methods
Mice
C57BL/6 mice were obtained from the Centre for Animal
Resources of the National University of Singapore. Generation of
CD1372/2 mice on a C57Bl/6 background has been described
previously [22]. CD1372/2 mice were bred in-house under
specific pathogen-free (SPF) conditions. All experiments were
conducted at the National University of Singapore. The experi-
mental protocol was approved by the National University of
Singapore Institutional Animal Care and Use Committee (NUS
IACUC). Institutional guidelines for animal care and use were
followed throughout the experiments. At the designated time
points for cell or tissue harvesting, mice were sacrificed by CO2-
asphyxiation. During the course of DSS treatment, mice were
checked daily for signs of distress or advanced colitis: Animals
losing above 20% of their original body weight or showing signs of
distress (e.g. apathy, aggressive behavior upon contact, unphysi-
ological bodily posture, shaggy fur) were sacrificed immediately by
CO2-asphyxiation. No additional analgetics were used during the
course of the experiments.
DSS-induced Acute Colitis in Mice
DSS-induced acute colitis in mice is a well-established model of
human IBD [23,24]. In pilot experiments, six to eight week-old
CD1372/2 and wild-type (WT) mice were administered 3.5%
Dextran Sodium Sulfate (DSS, MW 36.000–50.000, MP Biome-
dicals) in drinking water ad libitum versus tap water control over a
period of 7 days. Water consumption was monitored and was
comparable between the different groups. Weight loss, stool
consistency as well as stool occult blood tests (Hemocare-Test,
Care Diagnostica) were monitored daily to provide an assessment
of colitis severity during the experiment. At day 7, mice were
sacrificed, the intestines were removed, washed in ice-cold
phosphate-buffered saline (PBS), and samples were harvested,
fixed in 10% formalin for 24 h and embedded in paraffin to
provide sections for histological scoring of inflammation severity.
To study the resolution of inflammation, CD1372/2 and WT
mice were administered 2.0% DSS in drinking water ad libitum
versus tap water control over a period of 5 days. After 5 days of
DSS exposure, all mice were switched back to tap water for an
additional period of 0 to 7 days. Water consumption was
monitored and was comparable between the different groups.
Weight loss, stool consistency as well as stool occult blood tests
were monitored daily to provide an assessment of colitis severity
during the experiment. At the designated time points (day 5, day 8
and day 11 of the experiment), mice were sacrificed, the intestines
were removed, washed in ice-cold PBS, and samples were
harvested, fixed in 10% formalin for 24 h and embedded in
paraffin to provide sections for histological scoring of inflammation
severity. Additional samples were harvested for evaluation of
cytokine secretion in colonic segment cultures, as described below.
Additional sets of mice were sacrificed at the designated time
points (day 5 and day 8 of the experiment) for evaluation of lamina
propria mononuclear cell compartments, as described below.
Histological Evaluation of DSS-induced Colitis Severity
Histological evaluation of DSS-induced colitis severity was
performed as previously described [25]. Briefly, paraffin-embed-
ded colonic cross-sections were stained with Hematoxylin-Eosin
and evaluated under a light microscope by an experienced
investigator blinded to the experimental conditions. The distal
colon was evaluated since it has been demonstrated to be the most
severely affected colon segment in DSS-induced colitis [23,26],
and to provide a score representing the disease severity in the
entire colon [27]. Coded sections were scored using a validated
scoring system developed by Cooper [23] and Dieleman [28], and
modified by Williams [27] using a scale of 0 to 40. For each
animal, 2 sections approximately 400 mm apart were scored and
averaged.
Evaluation of Cytokine Secretion in Colon Segment
Tissue Cultures
Cytokine secretion was evaluated in cultures of colon segments
as previously described by other groups [29,30]. Briefly, mice were
sacrificed, the intestines were removed, opened lengthwise and
washed in PBS. After being cut into pieces of approximately 1 cm,
colon segments were shaken vigorously for 30 min in PBS. Tissue
segments of approximately 50 to 100 mg were then divided into
wells of a 24-well tissue culture plate and cultured in triplicates at
37uC for 24 h in 1 ml of complete medium containing penicillin/
streptomycin, gentamycin and amphotericin B. Culture superna-
tants were then collected and stored at 220uC until further
evaluation.
Cytokine concentrations in culture supernatants were evaluated
using ELISA kits (R&D Systems) according to the manufacturer’s
specifications. Cytokine concentrations are expressed per g of
colonic tissue.
Isolation of IEL and LPMNC and Flow Cytometry
Isolation of intestinal lymphocytes from both epithelial (IEL)
and lamina propria (LPMNC) compartments of the large intestine
was performed as previously described [31,32]. Briefly, mice were
sacrificed, the large intestines were removed, opened lengthwise
and washed in PBS. After cutting the colon into small pieces, the
intestinal epithelial layer was selectively detached by treatment
with 1 mM DTT in a shaker water-bath at 37uC for 30 min,
followed by vortexing for 20 sec. The supernatant containing IEL
and epithelial cells was then collected.
The residual tissues were incubated in a shaker water-bath at
37uC for 1 h with collagenase D (1 mg/ml) (Roche) and then
disrupted mechanically through a 70 mm cell strainer. IEL and
LPMNC fractions were further purified by Percoll (Sigma-Aldrich)
density gradient centrifugation. Mononuclear cells enriched in the
interface between 70 and 30% Percoll were recovered.
Freshly isolated intestinal IEL and LPMNC single cell
suspensions were washed in staining buffer (5% FBS/0.02%
NaN3 in PBS), blocked with anti-CD16/32 antibody for 5 min at
RT and then stained for 30 min at 4uC with the following surface
antibodies: anti-CD45-V500 (BD Pharmingen), anti-CD3 A700,
anti-CD4 PB (BD Pharmingen), anti-CD8 FITC, anti-CD11b PE,
anti-Ly6C APC, anti-Ly6G PE-Cy7, and with a live/dead fixable
dead stain kit in the far red fluorescent APC-Cy7 (Invitrogen). Cell
suspensions were then washed and analyzed using an LSRFortessa
flow cytometer (BD Biosciences) and FlowJo software (Version
9.3.1, Treestar). Unless otherwise stated antibodies were from
eBioscience.
Statistical Analysis
Data are expressed as mean 6 SEM. Prism software (Version 5,
GraphPad software) was employed to analyze the data using the
Student T-test. p,0.05 was considered statistically significant.
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Results
CD1372/2 and WT Mice Develop a Similar Disease
Severity in Acute 3.5% DSS-induced Colitis
We first examined the impact of an acute 3.5% DSS challenge
in CD1372/2 versus WT mice, which induces acute large bowel
inflammation [23,24]. Mice were given 3.5% DSS in drinking
water ad libitum for a period of 7 days, after which time mice were
sacrificed. The intestines were removed and sections were
embedded for histological scoring of inflammation severity.
Weight loss, stool consistency as well as stool occult blood tests
were used to monitor colitis severity in mice throughout the
experiment.
No difference was observed in CD1372/2 versus WT mice in
colitis severity during the 3.5% DSS challenge as measured by
weight loss (Fig. 1A), stool consistency as well as stool occult blood
tests (data not shown). Histological assessment of colitis severity
demonstrated a similar degree of inflammation both after 4 days of
3.5% DSS challenge (data not shown) as well as after 7 days of
3.5% DSS challenge (Fig. 1B). No histological signs of inflamma-
tion or weight loss were observed in water control treated animals
(Fig. 1A and data not shown). Thus, CD1372/2 and WT mice
develop a similar disease severity in acute 3.5% DSS-induced
colitis.
CD1372/2 Mice Show Increased Weight Loss during the
Resolution Phase After a 2.0% DSS Challenge
We next investigated whether CD137 influences the resolution
of intestinal inflammation. CD1372/2 and WT mice were given
2.0% DSS in drinking water ad libitum for a period of 5 days, after
which time mice were switched back to water to allow subsiding of
the colonic inflammation. At different time points after DSS
withdrawal mice were sacrificed, the intestines were removed and
sections were embedded for histological scoring of inflammation
severity.
CD1372/2 mice demonstrated an increased weight loss during
the resolution phase of intestinal inflammation after DSS
withdrawal compared to WT mice (Fig. 2A). Kaplan-Meier-
Analysis using a combined end-point of weight-loss above 20% of
original weight/death demonstrated a significantly increased drop-
out rate in CD1372/2 mice as compared to WT mice after DSS
withdrawal (Fig. 2B). Also the surviving CD1372/2 mice
demonstrated significantly increased histological inflammation 7
days after DSS withdrawal compared to WT mice (data not
shown). Besides histological examination, shortening of the colon
can be used as a measure of inflammation. We found significant
colonic shortening 3 days after DSS withdrawal in both CD1372/
2 and WT mice as compared to untreated mice, and significantly
shorter colons in CD1372/2 DSS-treated mice than in WT DSS-
treated mice (Fig. 2C). These results indicate that resolution of
intestinal inflammation is impaired in CD1372/2 mice.
Resolution of Inflammation After DSS Withdrawal is
Impaired in CD1372/2 Mice
To assess the development of inflammation after 2.0% DSS
exposure, CD1372/2 and WT mice were divided into two groups
each. One group of mice was sacrificed after 5 days of 2.0% DSS
exposure, while the other group of mice was allowed to resolve
intestinal inflammation for an additional 3 days on drinking water.
CD1372/2 and WT mice developed a similar degree of colitis
severity after 5 days of 2.0% DSS exposure as assessed by
histological criteria (Fig. 3A, B). However, while in WT mice
inflammation did not progress after withdrawal of DSS, CD1372/
2 mice showed a histological progression towards severe colonic
inflammation (Fig. 3A, B). These histological results correlate with
the increased weight loss and increased drop-out rate observed in
CD1372/2 mice after 2.0% DSS exposure (Fig. 2A, B). In
summary, CD1372/2 and WT mice develop a similar histologic
disease severity after 5 days of acute 2.0% DSS exposure, however,
resolution of inflammation after withdrawal of DSS is impaired in
CD1372/2 mice.
2.0% DSS-induced Colitis Leads to Increased Local
Colonic IFN-c, GM-CSF, CXCL1 and IL-17 Secretion in
CD1372/2 Mice
Having observed a difference in the resolution of inflammation
we investigated whether this is reflected and possibly attributable
to a difference in the cytokine profile between CD1372/2 and WT
mice. Thus, mice were exposed to 2.0% DSS for a period of 5
days, or to 5 days DSS plus an additional 3 days with normal
water, after which time animals were sacrificed. Local cytokine
secretion in colon segment cultures was then evaluated using
previously published techniques [29,30]. Interestingly, colon
segments of CD1372/2 mice that were exposed for 5 days to
2.0% DSS exhibited increased IFN-c secretion compared to colon
segments of WT mice with the same treatment, indicating a
stronger Th1-type colonic inflammatory response in the absence of
Figure 1. CD1372/2 and WT mice develop a similar disease severity in acute 3.5% DSS-induced colitis. A, Percentage of body weight
loss over the course of 7 days of treatment with 3.5% DSS. B, Histology score of WT (black bars) and CD1372/2 (white bars) mice treated with 3.5%
DSS for 7 days. Data are representative of two independent experiments, shown here are means6 SEM, n = 15 for DSS groups, n = 5 for water control
groups.
doi:10.1371/journal.pone.0073277.g001
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CD137 (Fig. 4A). Additionally, the colon segments from the
CD1372/2 mice had an increased GM-CSF, IL-17 and CXCL1
secretion which points to an increased pro-inflammatory neutro-
phil response (Fig. 4B, G, H). Of note, increased levels of IL-17
secretion after colitis induction indicate increased numbers of
Th17 cells (Fig. 4G). Secretion of IL-2, which is important for
growth, proliferation and differentiation of T cells, was reduced in
colon segment cultures of 2.0% DSS-exposed CD1372/2
compared to WT mice, however, the difference did not reach
statistical significance (Fig. 4C). The levels of TGF-ß, TNF-a, G-
CSF and CXCL2 did not significantly vary between the two
mouse strains (Fig. 4D–F, I). It should be emphasized that the
cytokine secretion profiles were observed after 5 days of 2.0%
DSS-exposure, at a time when histologically there were no
differences detectable in the severity of the colonic inflammatory
response (Fig. 3A, B).
Of note, no differences were observed in systemic cytokine
profiles (IL-6, IL-10, IL-13, IL-17A, IFN-c, TNF-a, GM-CSF) as
measured in whole blood drawn after 5 days of 2.0% DSS-
exposure as well as 8 days and 11 days post DSS treatment (data
not shown). In summary, 2.0% DSS-induced colitis is accompa-
nied by increased local colonic IFN-c, GM-CSF, CXCL1 and IL-
17 secretion in CD1372/2 compared to WT mice.
CD1372/2 Mice have Increased Numbers of Neutrophils
during the Resolution of DSS-induced Inflammation
In addition to the altered cytokine profile we asked whether the
different histopathology observed in WT and in CD1372/2 mice
was accompanied by a change in the infiltrating leukocyte subsets
in the colonic mucosal lamina propria. The specific subsets of
lamina propria mononuclear (inflammatory) cells contributing to
the increased DSS-induced colitis were characterized in mice that
received 5 days of 2.0% DSS treatment, followed by a resolution
phase of 3 days. On days 5 and 8, mice were sacrificed, the large
intestines were removed and the intestinal lymphocytes from both
epithelial (IEL) and lamina propria (LPMNC) compartments of
the large intestine were isolated as described previously [31,32],
and were analyzed by flow cytometry.
There was minimal cellular infiltrate with no difference in the
subsets of intestinal lamina propria mononuclear cells (LPMNC) in
CD1372/2 versus WT mice 5 days after 2.0% DSS exposure (data
not shown). However, 3 days after withdrawal of DSS, CD1372/2
mice had significantly increased numbers of neutrophilic granu-
locytes in the LPMNC subset, reflecting the increased inflamma-
tion (Fig. 5A, B). At the same time, CD1372/2 mice had
significantly decreased numbers of macrophages in the IEL subset
compared to WT mice (Fig. 5A, D). Since macrophages have been
demonstrated to be necessary for intestinal regenerative responses
to injury [33], these observations suggest an impaired colonic
restitution in CD1372/2 mice. No differences were observed in
the numbers of monocytes, B cells, NK cells, dendritic cells, CD4+
or CD8+ T cells, neither among the LPMNC (B, C) or the IEL (D,
E), nor in untreated CD1372/2 versus WT mice (data not shown).
In summary, the decreased number of macrophages that are
necessary for mucosal healing, together with the increased
recruitment of neutrophils to the lamina propria of CD1372/2
mice may explain the increased severity of DSS-colitis in these
mice.
Discussion
The current study investigated DSS-induced colitis in CD1372/
2 and WT mice. We found that in the absence of CD137, mice
develop a more severe colitis, suggesting that CD137 exerts an
anti-inflammatory effect in this model.
Of note, both CD1372/2 and WT mice demonstrated a similar
degree of inflammation after 5 days of DSS exposure. However,
the resolution of colonic inflammation was significantly impaired
in CD1372/2 mice. This led to prolonged tissue infiltration of
leukocytes, an increased neutrophil/macrophage ratio among the
infiltrating cells and an increased release of the pro-inflammatory
cytokines IFN-c, GM-CSF, CXCL1 and IL-17.
The reason for the more pronounced disease manifestation in
the CD1372/2 mice may be due to several factors. Overexpres-
sion of the granulocyte survival factor GM-CSF has been
associated with suppression of neutrophil apoptosis in the absence
of CD137 activation [34]. It has been shown in vitro that CD137
is constitutively expressed on neutrophilic granulocytes, and that
the CD137 signaling pathway blocks the anti-apoptotic effect
mediated by the 1-subunit of the GM-CSF receptor in neutrophils
[35]. Therefore, the more severe disease manifestation in the
CD1372/2 mice may be due to the absence of CD137-mediated
granulocyte apoptosis leading to increased granulocyte accumu-
lation and subsequent tissue damage, since mucosal inflammation
in DSS-induced colitis is mediated by neutrophilic granulocytes
[36,37]. In line with this hypothesis and published data, we found
Figure 2. Increased susceptibility of CD1372/2mice during the resolution phase after 5 days of 2.0% DSS treatment as compared to
WT mice. A, Percentage of body weight loss over the course of 5 days of treatment with 2.0% DSS water followed by 7 days of normal water. B,
Kaplan-Meier-Analysis using a combined end-point of weight-loss above 20% of original weight/death in 5 days 2.0% DSS treated mice followed by 7
days of recovery phase with normal water. C, Colon length of mice untreated or treated for 5 days with 2.0% DSS followed by 3 days of normal water.
Data are representative of at least three independent experiments, shown here are means 6 SEM, n = 10–15 for DSS groups, n = 5 for water control
groups (* p,0.05).
doi:10.1371/journal.pone.0073277.g002
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increased GM-CSF in the colons of CD1372/2 mice, which likely
supported neutrophil accumulation in the colons. Additionally, we
found increased levels of CXCL1 in colitic CD1372/2 mice,
which increase neutrophil influx into the inflamed mucosal tissue.
Remarkably, increased levels of IL-17 in CD1372/2 mice indicate
increased numbers of Th17 cells, which is further supporting
neutrophil recruitment [38]. Although the initial infiltration by
neutrophils is beneficial for killing bacteria, it is presumed that it is
the persistent presence of neutrophils in the tissues that causes
damage [36,37]. Of note, it has recently been demonstrated in a
T-cell transfer model of colitis that GM-CSF skews hematopoietic
stem and progenitor cells towards granulocyte-monocyte progen-
itor cells, leading to the exacerbation of intestinal inflammation.
Importantly, colitis could be ameliorated by GM-CSF blockade
[39]. Thus, the GM-CSF driven increased accumulation and
Figure 3. CD1372/2 and WT mice develop a similar histologic disease severity after 5 days of acute 2.0% DSS exposure, however,
resolution of inflammation after withdrawal of DSS is impaired in CD1372/2 mice. A, Representative histologic colonic cross-sections of
mice exposed to normal water (control), 5 days of 2.0% DSS water ((+)DSS Day 5) and 5 days of 2.0% DSS water followed by 3 days normal water
((+)DSS Day 8) stained with Hematoxylin-Eosin (20-fold magnification). B, Histology score of WT (black bars) and CD1372/2 (white bars) mice
untreated, treated with 2.0% DSS for 5 days or mice treated with 2.0% DSS for 5 days followed by 3 days of normal water. Data are representative of
two independent experiments, shown here are means 6 SEM, n = 4 per group (*** p,0.001).
doi:10.1371/journal.pone.0073277.g003
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prolonged presence of neutrophils in the colons of CD1372/2
mice can explain the increased tissue damage in these mice.
There is an additional function of CD137, whose absence in the
CD1372/2 mice is likely to contribute to the more severe disease
manifestation: CD137 not only regulates the activities of mature
leukocytes, it also regulates hematopoiesis, and has been shown to
induce proliferation and expansion of hematopoietic progenitor
cells. Concomitantly, CD137 induces myeloid differentiation, and
within the myeloid lineage monocytic differentiation [40,41],
especially during inflammation [42]. In fact, CD137 and G-CSF
compete for driving the differentiation of myeloid progenitor cells
into the monocytic and granulocytic differentiation, respectively,
with an increasing G-CSF/CD137 ratio leading to a preponder-
ance of granulocytes [43]. In the absence of CD137 more myeloid
precursor cells would be expected to differentiate to granulocytes
at the expense of monocytes and macrophages. Indeed, we not
only see an increase of granulocytes in the colons CD1372/2
compared to WT mice as a response to DSS administration but
also a decrease in macrophages. This increased granulocyte/
macrophage ratio could not only contribute to the more severe
colitis in the CD1372/2 mice through recruiting more granulo-
cytes that in turn cause tissue damage but also because
macrophages are the cells that coordinate wound healing [33].
With fewer macrophages being present in the colons of the
CD1372/2 mice, resolution of inflammation and wound healing
are expected to be delayed, and that is what we observe.
The CD137 receptor/ligand system has so far been mainly
associated with proinflammatory effects. Agonistic anti-CD137
antibodies costimulate T cells, and enhance immunity leading to
rejection of tumors and transplants in mice, and enhance anti-
virus immune responses [5,44,45,46]. Further, bidirectional
signaling exists for the CD137 receptor/ligand system, and reverse
signaling of CD137L activates antigen presenting cells, which
leads to a further enhancement of immune responses [47]. The
proinflammatory activities of CD137 and CD137L are also
evident in autoimmune diseases. The administration of antago-
nistic anti-CD137 ligand antibodies to mice with collagen-induced
arthritis resulted in a milder disease [48]. Further, experimental
Figure 4. 2.0% DSS-induced colitis leads to increased local colonic IFN-c, GM-CSF, CXCL1 and IL-17 secretion in CD1372/2 versus
WTmice. Colon segment culture supernatants of CD1372/2 (white bars) and WT mice (black bars) untreated (day 0), or treated either for 5 days with
2% DSS (day 5) or 5 days with 2% DSS followed by 3 days with normal water (day 8), were examined for IFN-c (A), GM-CSF (B), IL-2 (C), TGF-1 (D), TNF-
a (E), G-CSF (F), IL-17 (G), CXCL1 (H) and CXCL2 (I). Data are representative of two independent experiments, shown here are means 6 SEM, n = 4 per
group (* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0073277.g004
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autoimmune encephalomyelitis is more severe in mice that are
deficient in CD137L [49]. However, the very same agonistic anti-
CD137 antibodies that enhance anti-tumor immunity have been
shown to quench autoimmunity and to ameliorate autoimmune
diseases, including experimental autoimmune encephalomyelitis
and type 1 diabetes [8,9,10,50,51]. An explanation for these
puzzling findings and seemingly contradictory activities has not yet
been found. These examples demonstrate that the consequences of
modulating the CD137 receptor/ligand system are difficult to
predict in autoimmune diseases. Nevertheless, our findings in the
Figure 5. CD1372/2 mice have increased numbers of neutrophils in the lamina propria mononuclear cell (LPMNC) subpopulations
while presenting lower macrophage numbers in the intraepithelial (IEL) subpopulation. A, Gating strategy for myeloid (top panel) and
lymphocyte (lower panel) populations. B, Quantification of different immune cell populations in the LPMNC cells (B, C) and IEL cells (D, E) during the
resolution phase of inflammation 3 days after withdrawal of 2.0% DSS. Data represent means 6 SEM of 4 independent experiments pooled together,
n = 3–10 per group (* p,0.05). Mo (Monocytes), Neutro (Neutrophils), Macro (Macrophages), DCs (Dendritic cells), NK (Natural Killer cells).
doi:10.1371/journal.pone.0073277.g005
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DSS colitis model suggest that neutralizing CD137 with antago-
nistic anti-CD137 antibodies would not be beneficial for the
treatment DSS-induced colitis and possibly also not for IBD
patients. Our data suggest that agonistic anti-CD137 antibodies
may be more suited to ameliorate colitis.
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